ClinicalTrials.gg
RecruitingNCT07701811AF-AIUpdated Sep 9, 2026

AI-Assisted Written Information in Chronic Anal Fissure

An interventional study of AI-assisted written patient information and Standardized verbal counseling in Chronic Anal Fissure, sponsored by Sanliurfa Education and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Sanliurfa Education and Research Hospital · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This single-center, prospective, 1:1 randomized, parallel-group controlled superiority trial compares standard verbal counseling with AI-assisted written patient information in adults with primary chronic anal fissure receiving initial medical/conservative treatment. The primary objective is to determine whether AI-assisted written information improves complete treatment adherence at day 14. Secondary objectives include pain and discomfort outcomes, Patient Global Impression of Change, HEMO-FISS-QoL change, stool form change, additional healthcare visits, transition to interventional treatment, and patient satisfaction.

Read the detailed description

This is a single-center, prospective, 1:1 randomized, parallel-group, superiority-type controlled trial. Adult patients with primary chronic anal fissure for whom initial medical/conservative treatment is planned will be enrolled. Participants will be randomized in a 1:1 ratio to two groups. The control group will receive standardized verbal counseling, whereas the intervention group will receive AI-assisted written patient information containing the same medical content and pre-validated by the investigators. The medical treatment regimen will be identical in both groups, and the only difference will be the method of patient information delivery. Assessments will be performed face-to-face at baseline, by telephone on days 7 and 14, and face-to-face at week 6. The primary endpoint is complete treatment adherence at day 14. Secondary outcomes include changes in pain and discomfort at days 7 and 14 and week 6, PGI-C, change in HEMO-FISS-QoL score, change in stool form, additional healthcare visits, need for interventional treatment, and patient satisfaction.

02

Conditions studied

  • Chronic Anal Fissure

Keywords

  • Anal fissure
  • Chronic anal fissure
  • Treatment adherence
  • AI-assisted patient information
  • HEMO-FISS-QoL
  • PGI-C
  • Conservative treatment
03

In context

Fissure in Ano

84 studies on the registry are indexed under Fissure in Ano; 16 are open to participants now.

This study's planned enrollment of 220 is above the median of 99 across 65 interventional studies indexed under Fissure in Ano.

Browse Fissure in Ano studies →

Lead sponsor

Sanliurfa Education and Research Hospital is the lead sponsor of 25 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older
  2. Clinical diagnosis of primary chronic anal fissure
  3. Initial medical/conservative treatment planned at first evaluation
  4. Ability to read and understand Turkish
  5. Reachable by telephone
  6. Provision of written

Exclusion criteria

Exclusion Criteria:

  1. Acute anal fissure
  2. Suspicion or diagnosis of secondary fissure (including Crohn's disease, tuberculosis, -related lesion, suspected , or atypical lateral fissure)
  3. Planned botulinum toxin, surgery, or another interventional treatment
  4. History of botulinum toxin or surgical treatment for anal fissure within the last 6 months
  5. Concomitant perianal abscess, fistula, advanced hemorrhoidal disease, or another significant anorectal pathology
  6. Pregnancy and early postpartum period
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    AI-assisted written patient information

    Participants receive standardized medical treatment plus AI-assisted written patient information that contains the same medical content as the verbal counseling and has been pre-validated by the investigators.

    Behavioral: AI-assisted written patient information

  • Active comparator
    Standardized verbal counseling

    Participants receive standardized medical treatment plus standardized verbal counseling alone.

    Behavioral: Standardized verbal counseling

Interventions

  • BehavioralAI-assisted written patient information

    Investigator-validated written patient information prepared with AI assistance and provided in addition to standard medical treatment.

  • BehavioralStandardized verbal counseling

    Standardized verbal counseling regarding medical treatment and lifestyle measures, provided in addition to standard medical treatment.

06

What researchers measure

Primary outcomes

  1. Complete treatment adherence at Day 14

    Complete treatment adherence at Day 14, defined as a total adherence score of at least 5 out of 6 predefined treatment-behavior items: regular topical medication use, correct application to the target area, regular stool softener or fiber support, achievement of the water intake target, regular warm sitz bath or warm water application, and avoidance of excessive straining.

    Time frame: Day 14

Secondary outcomes

  1. Pain during defecation at Day 7

    Pain during defecation assessed using a 0 to 10 Visual Analog Scale, where 0 indicates no pain and 10 indicates the worst imaginable pain; higher scores indicate worse pain.

    Time frame: Day 7

  2. Pain during defecation at Day 14

    Pain during defecation assessed using a 0 to 10 Visual Analog Scale, where 0 indicates no pain and 10 indicates the worst imaginable pain; higher scores indicate worse pain.

    Time frame: Day 14

  3. Pain during defecation at Week 6

    Pain during defecation assessed using a 0 to 10 Visual Analog Scale, where 0 indicates no pain and 10 indicates the worst imaginable pain; higher scores indicate worse pain.

    Time frame: Week 6

  4. Patient Global Impression of Change at Day 7

    Patient Global Impression of Change assessed on a 7-category ordinal scale: very much improved, much improved, a little improved, unchanged, a little worse, much worse, and very much worse.

    Time frame: Day 7

  5. Patient Global Impression of Change at Week 6

    Patient Global Impression of Change assessed on a 7-category ordinal scale: very much improved, much improved, a little improved, unchanged, a little worse, much worse, and very much worse.

    Time frame: Week 6

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared because this is a single-center study involving sensitive patient-level clinical data, and there is no pre-specified institutional mechanism for external data sharing. Only aggregated, de-identified study results will be reported.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2026, 5 months after the start.

Of 25 interventional studies with no phase under Fissure in Ano, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2026
First posted
Jul 14, 2026
StartActual
Jul 15, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07701811
Lead sponsor
Sanliurfa Education and Research Hospital
Responsible party
Vedat Kaplan (Principal Investigator, Sanliurfa Education and Research Hospital) — Principal investigator
First posted
Jul 14, 2026
Start date
Jul 15, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 9, 2026

Study contacts

Vedat Kaplan
Contact
vedat_kaplan_@hotmail.com
+905459045165

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion